- Home
- BVS vs RIGL Comparison
BVS vs RIGL Comparison
Compare BVS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVS | RIGL |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 537.6M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BVS | RIGL |
|---|---|---|
| Price | $7.05 | $49.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.33 | ★ $43.20 |
| AVG Volume (30 Days) | 315.2K | ★ 624.0K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 0.15 | ★ 6.20 |
| Revenue | ★ $563,829,000.00 | $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $7.11 | $0.22 |
| P/E Ratio | $46.17 | ★ $7.90 |
| Revenue Growth | 1.58 | ★ 79.13 |
| 52 Week Low | $5.81 | $14.63 |
| 52 Week High | $11.89 | $52.24 |
Technical Indicators
Market Signals| Indicator | BVS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 64.29 |
| Support Level | $7.39 | $43.81 |
| Resistance Level | $7.66 | $52.24 |
| Average True Range (ATR) | 0.39 | 3.35 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 45.49 | 75.13 |
Price Performance
Historical ComparisonAbout BVS Bioventus Inc.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.